COVID‐19 Vaccine Safety in Pregnancy, A Nested Case–Control Study in Births From April 2021 to March 2022, England
BJOG: An International Journal of Obstetrics & Gynaecology · 2024
DOI: 10.1111/1471-0528.17949 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJOG: An International Journal of Obstetrics & Gynaecology, 2024. Verfasst von Anna A Mensah und 8 weiteren Autor:innen. Beteiligte Einrichtung: UK Health Security Agency, London, UK. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, SARS-CoV-2, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Assessment of COVID‐19 vaccine safety in pregnancy using population‐based data.
Design
Matched case–control study nested in a retrospective cohort.
Setting
April 2021–March 2022, England. Population or Sample All pregnant individuals aged between 18 and 50 years with valid health records.
Methods
Individuals identified from the national Maternity Services Data Set (MSDS) had their records linked to hospital admission, national COVID‐19 vaccine and COVID‐19 testing databases. Matching included participant's age and estimated week of conception. We compared outcomes across multiple COVID‐19 vaccine exposures using conditional multivariable logistic regression, adjusting for demographic and health characteristics. Main Outcome Measures Adverse pregnancy, maternal and neonatal outcomes.
Results
514 013 individuals were included. We found lower odds of giving birth to a baby who was low birthweight (aOR = 0.86, 95% CI: 0.79–0.93), preterm (aOR = 0.89, 95% CI: 0.85–0.92) or who had an Apgar score < 7 at 5 min of age (aOR = 0.89, 95% CI: 0.80–0.98) for individuals who received at least one dose of COVID‐19 vaccine during pregnancy. The odds of admission to intensive care unit during pregnancy were lower in those vaccinated (aOR = 0.85, 95% CI: 0.76–0.95). There was no association between vaccination in pregnancy and stillbirth, neonatal death, perinatal death and maternal venous thromboembolism in pregnancy.
Conclusions
COVID‐19 vaccines are safe to use in pregnancy. Our findings generated important information to communicate to pregnant individuals and health professionals to support COVID‐19 maternal vaccination programmes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- UK Health Security Agency, London, UK.
- Women's Health Research Unit, Centre for Public Health and Policy, Queen Mary University of London, London, UK.
- NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, UK.
- NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, UK.
ORCID-Profile: Anna A Mensah, Jennifer E Jardine, Tom Clare
Zitieren
APA
Mensah, A. A., Stowe, J., Jardine, J. E., Kirsebom, F. C. M., Clare, T., Kall, M., Campbell, H., Lopez-Bernal, J., & Andrews, N. (2024). COVID‐19 Vaccine Safety in Pregnancy, A Nested Case–Control Study in Births From April 2021 to March 2022, England. BJOG: An International Journal of Obstetrics & Gynaecology. https://doi.org/10.1111/1471-0528.17949
Vancouver
Mensah AA, Stowe J, Jardine JE, Kirsebom FCM, Clare T, Kall M, et al. COVID‐19 Vaccine Safety in Pregnancy, A Nested Case–Control Study in Births From April 2021 to March 2022, England. BJOG: An International Journal of Obstetrics & Gynaecology. 2024. doi:10.1111/1471-0528.17949
BibTeX
@article{Mensah2024,
author = {Mensah, Anna A and Stowe, Julia and Jardine, Jennifer E and Kirsebom, Freja C M and Clare, Tom and Kall, Meaghan and Campbell, Helen and Lopez-Bernal, Jamie and Andrews, Nick},
title = {COVID‐19 Vaccine Safety in Pregnancy, A Nested Case–Control Study in Births From April 2021 to March 2022, England},
journal = {BJOG: An International Journal of Obstetrics & Gynaecology},
year = {2024},
doi = {10.1111/1471-0528.17949}
}
EUVIMED